title: Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.
abstract: Anti-tumor-associated glycoprotein (TAG)-72 PEG-immunoliposomes (PILs) were prepared by conjugation of Fab' fragments of recombinant humanized monoclonal antibody, HuCC49, to sterically stabilize unilamellar liposomes (90-110 nm in diameter) to target TAG-72-overexpressing cancer cells. The liposomes consisted of 1-palmitonyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 92 mol percent, O,O'-dymyrisyl-N-lysyl aspartate (DMKD cationic lipid), 4 mol percent, distearoyl-phosphatidyl-ethanolamine-polyethylene glycol 2000 (DSPE-PEG(2000)), 3 mol percent and DSPE-maleimide (DSPE-PEG(2000)-Mal), 1 mol percent. These anti-TAG-72 PILs were able to adhere to the surface of TAG-72-overexpressing LS174 T human colon cancer cells more effectively than conventional liposomes. Also, in vitro gene transfection of the LS174 T cells by the anti-TAG-72 PILs in the presence of a high concentration of fetal bovine serum (up to 60%) was greater than that by conventional cationic lipoplexes. Intravenously administered anti-TAG-72 PILs efficiently localized in the LS174 T tumor tissues, while the non-targeted conventional liposomes did not. Intravenous administration of the anti-TAG-72 PILs containing plasmids encoding antiangiogenic proteins, such as angiostatin K1/3, endostatin and saxatilin, significantly inhibited in vivo growth of LS174 T tumors and angiogenesis in the tumor tissues. These results demonstrated the potential of TAG-72-mediated targeting of immunoliposomes as a modality for systemic gene delivery to human colon cancer cells.
authors.affiliation: Department of Biomedical Laboratory Science, Institute of Health Science, Yonsei University, Wonju, Republic of Korea.
authors.forename: K S
authors.initials: KS
authors.lastname: Kim
authors.forename: Y K
authors.initials: YK
authors.lastname: Lee
authors.forename: J S
authors.initials: JS
authors.lastname: Kim
authors.forename: K H
authors.initials: KH
authors.lastname: Koo
authors.forename: H J
authors.initials: HJ
authors.lastname: Hong
authors.forename: Y S
authors.initials: YS
authors.lastname: Park
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D016466:CHO Cells; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000628:therapy*; D006224:Cricetinae; D003412:Cricetulus; D015316:Genetic Therapy / Q000379:methods*; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008081:Liposomes; D010957:Plasmids
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006023:Glycoproteins; D007140:Immunoglobulin Fab Fragments; D008081:Liposomes; C047052:tumor-associated antigen 72